Cbay stock forecast.

28/12/2022 ... Impact of many factors on the stock prices makes the stock prediction a difficult and highly complicated task.The Coterra stock price fell by -1.87% on the last day (Monday, 27th Nov 2023) from $26.77 to $26.27. During the last trading day the stock fluctuated 1.82% from a day low at $26.12 to a day high of $26.59. The price has been going up and down for this period, and there has been a -2.6% loss for the last 2 weeks.American ingenuity has lengthy been the driving power behind the US financial system, and few sectors embody this higher than biotech. With over 500 biotech companies working within the US, creating new medical applied sciences, drug therapies, surgical devices, and methods – the record is barely restricted by creativeness.The CymaBay Therapeutics stock forecast for tomorrow is $ 19.01, which would represent a -0.48% loss compared to the current price. In the next week, the price of CBAY is expected to decrease by -5.95% and hit $ 17.96. As far as the long-term CymaBay Therapeutics stock forecast is concerned ...Dec 1, 2023 · According to the issued ratings of 12 analysts in the last year, the consensus rating for CymaBay Therapeutics stock is Buy based on the current 11 buy ratings and 1 strong buy rating for CBAY. The average twelve-month price prediction for CymaBay Therapeutics is $22.27 with a high price target of $34.00 and a low price target of $12.00.

Stock Price Forecast. The 10 analysts offering 12-month price forecasts for Viking Therapeutics Inc have a median target of 34.00, with a high estimate of 40.00 and a low estimate of 28.00. The ...

97.32M. MSFT. 374.51. -1.16%. 29.21M. View today's Cymabay Therapeu stock price and latest CBAY news and analysis. Create real-time notifications to follow any changes in the live stock price.

He kept his outperform rating on CBAY stock and raised his price target to 20 from 18. Notably, CymaBay stock has a best-possible Relative Strength Rating of 99, according to IBD Digital. This ...CBAY Stock 12 Months Forecast. $24.40. (29.93% Upside) Based on 10 Wall Street analysts offering 12 month price targets for CymaBay Therapeutics in the last 3 months. …CymaBay Therapeutics Inc. analyst ratings, historical stock prices, earnings estimates & actuals. CBAY updated stock price target summary.1 Wall Street research analysts have issued 12 month price objectives for Genus' shares. Their GNS share price targets range from GBX 4,500 to GBX 4,500. On average, they anticipate the company's stock price to reach GBX 4,500 in the next year. This suggests a possible upside of 126.4% from the stock's current price.

Stock Price Forecast The 1 analysts offering 12-month price forecasts for Creative Medical Technology Holdings Inc have a median target of 30.00, with a high estimate of 30.00 and a low estimate ...

CBAY stock performances on November 6, 2023, are expected to be positive based on the information provided. According to data from CNN Money, the 12 analysts offering 12-month price forecasts for CymaBay Therapeutics Inc have a median target of $22.50, with a high estimate of $33.00 and a low estimate of $19.00.

EXEL Stock 12 Months Forecast. Based on 13 Wall Street analysts offering 12 month price targets for Exelixis in the last 3 months. The average price target is $25.75 with a high forecast of $32.00 and a low forecast of $18.00. The average price target represents a 25.06% change from the last price of $20.59.This stock may move much during the day (volatility) and with periodic low trading volume this stock is considered to be "high risk". During the last day, the stock moved $0.0280 between high and low, or 8.46%.For the last week the stock has had daily average volatility of 7.18%.. Our recommended stop-loss: $0.325 (-3.60%) (This stock …What are analysts’ forecasts for CBAY stock? Forecst.com predicts future values using technical analysis of a large number of analytical parameters. CBAY stock returns are also predicted based on historical data. According to our research, CBAY stock is a bad long-term investment.Nov 21, 2023 · According to analyst projections, CBAY’s forecast low is $20.00 with $34.00 as the target high. To hit the forecast high, the stock’s price needs a -82.21% plunge from its current level, while the stock would need to soar -7.18% for it to hit the projected low. Cymabay Therapeutics Inc (CBAY) estimates and forecasts Analyst Forecast. According to 12 analysts, the average rating for CBAY stock is "Strong Buy." The 12-month stock price forecast is $22.64, which is an increase of 18.35% from the latest price.Their ZOM share price targets range from $6.00 to $6.00. On average, they expect the company's stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 3,421.1% from the stock's current price. View analysts price targets for ZOM or view top-rated stocks among Wall Street analysts.

Find the latest CymaBay Therapeutics, Inc. (CBAY) stock quote, history, news and other vital information to help you with your stock trading and investing.Get the latest information on CymaBay Therapeutics, Inc. (CBAY), a biopharmaceutical company focused on liver and other chronic diseases, including its stock price, …Sector. Consumer Non-Durables. Industry. Food: Specialty/Candy. No executives to display. Corporate headquarters. --, --. Find real-time BROS - Dutch Bros Inc stock quotes, company profile, news ...Cymabay Therapeutics (CBAY) Company Description. CymaBay Therapeutics Inc is a clinical-stage biopharmaceutical company. Its main business involves the development of therapeutics such as Arhalofenate, MBX-8025, and MBX-2982. These drugs are intended to treat serious metabolic disorders. Arhalofenate is used to treat gout, MBX-2982 is an oral ...Latest CBAY News | Press Releases See All CBAY News Today’s Trading Data as of 3:59pm ET, 11/20/2023 Growth & Valuation Competitors Data as of 4:00pm ET, 11/20/2023 Financials Profile... Based on short-term price targets offered by 11 analysts, the average price target for CymaBay Therapeutics Inc. comes to $22.73. The forecasts range from a low …

CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635 (c) (4) NEWARK, Calif., Nov. 17, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced …Dec 1, 2023 · 7 brokers have issued 12-month price targets for Verastem's stock. Their VSTM share price targets range from $21.00 to $36.00. On average, they anticipate the company's share price to reach $29.71 in the next year. This suggests a possible upside of 362.1% from the stock's current price. View analysts price targets for VSTM or view top-rated ...

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Q3 2023 Earnings Call Transcript November 7, 2023 CymaBay Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.32 EPS, expectations were $-0.3. Operator: Good day, ladies and gentlemen, and welcome to CymaBay’s Third Quarter 2023 ...Understanding stock price lookup is a basic yet essential requirement for any serious investor. Whether you are investing for the long term or making short-term trades, stock price data gives you an idea what is going on in the markets.CBAY is a biotechnology company that develops treatments for neurological disorders. The stock price forecast shows a strong buy signal from the 3-month …NEWARK, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic ... The Coterra stock price fell by -1.87% on the last day (Monday, 27th Nov 2023) from $26.77 to $26.27. During the last trading day the stock fluctuated 1.82% from a day low at $26.12 to a day high of $26.59. The price has been going up and down for this period, and there has been a -2.6% loss for the last 2 weeks.CBAY Stock Forecast: Positive Outlook and Analyst Consensus for CymaBay Therapeutics Inc. CBAY stock has been performing well in recent months, with positive forecasts from analysts. On June 30, 2023, the 10 analysts offering 12-month price forecasts for CBAY had a median target of $15.00, indicating a potential increase of …

Discover historical prices for CBAY stock on Yahoo Finance. View daily, weekly or monthly format back to when CymaBay Therapeutics, Inc. stock was issued.

ETNB Stock 12 Months Forecast. Based on 9 Wall Street analysts offering 12 month price targets for 89bio in the last 3 months. The average price target is $31.38 with a high forecast of $39.00 and a low forecast of $25.00. The average price target represents a 271.36% change from the last price of $8.45.

CBAY stock showed promising performance on November 8, 2023, according to data from CNN Money. The 12 analysts offering 12-month price forecasts for CymaBay Therapeutics Inc had a median target of 22.50, with a high estimate of 33.00 and a low estimate of 19.00.Being prepared to weather a hurricane — whether that involves fortifying your home or creating an emergency evacuation plan — is an important part of making it through the storm. Hurricanes travel across the ocean via massive, circular gust...Check out our CBAY stock analysis, current CBAY quote, charts, and historical prices for Cymabay Therapeutics stock ... CBAY Stock Predictions, Articles, and Cymabay Therapeutics News From ...A high-level overview of CymaBay Therapeutics, Inc. (CBAY) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.Nov 14, 2023 · CymaBay Therapeutics Stock Forecast 2023. In the last five quarters, CymaBay Therapeutics’s Price Target has fallen from $29.28 to $23.09 - a -21.14% decrease. Five analysts predict that CymaBay Therapeutics’s share price will fall in the coming year, reaching $10.00. This would represent a decrease of -56.69%. Cymabay Therapeutics Inc Stock Price Forecast, "CBAY" Predictons for2025CymaBay Therapeutics, Inc. is a clinical stage biopharmaceutical company, focused on developing and providing access to therapies for patients with liver and other chronic diseases with high unmet medical need. Its products include MBX-8025 and Arhalofenate, MBX-8025 aims to treat lipid and liver diseases while Arhalofenate intends to reduce ...(See CBAY stock forecast)Cerevel Therapeutics (CERE)The next Edelman choice is Cerevel, a company established in 2018 that specializes in the field of neuroscience. Cerevel's focus is on the ...Based on 10 Wall Street analysts offering 12 month price targets for CymaBay Therapeutics in the last 3 months. The average price target is $24.40 with a high forecast of $33.00 and a low forecast of $20.00. The average price target represents a 29.93% change from the last price of $18.78. Highest Price Target $33.00. Average Price Target $24.40.

CBAY Stock Forecast: Positive Outlook and Analyst Consensus for CymaBay Therapeutics Inc. CBAY stock has been performing well in recent months, with positive forecasts from analysts. On June 30, 2023, the 10 analysts offering 12-month price forecasts for CBAY had a median target of $15.00, indicating a potential increase of …Find real-time TNEYF - Tamarack Valley Energy Ltd stock quotes, company profile, news and forecasts from CNN Business.Analysts Offer Insights on Healthcare Companies: CymaBay Therapeutics (CBAY), Mersana Therapeutics (MRSN) and Verona Pharma (VRNA) November 8, 2023 TipRanks.Instagram:https://instagram. is land a good investment right nowapplovin.cheapest catastrophic health insurancetesla stock option chain At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life. ai earning dateares capital corp stock Newark, California-based CymaBay Therapeutics (CBAY) was approved for uplisting to the Nasdaq in June 2014, with stock initially trading at a value of $19. Across the next 9 years they have been ...16 Wall Street analysts have issued 12 month price targets for Exelixis' stock. Their EXEL share price targets range from $18.00 to $32.00. On average, they anticipate the company's stock price to reach $25.44 in the next twelve months. This suggests a possible upside of 18.3% from the stock's current price. View analysts price … tgan stock Jun 30, 2023 · What happened. Shares of CymaBay Therapeutics ( CBAY 4.87%) were up more than 37% as of 11:15 a.m. ET on Friday. The clinical-stage biotech saw its shares rise after Ipsen and Genfit announced ... According to analyst projections, CBAY’s forecast low is $20.00 with $34.00 as the target high. To hit the forecast high, the stock’s price needs a -82.21% plunge from its current level, while the stock would need to soar -7.18% for it to hit the projected low. Cymabay Therapeutics Inc (CBAY) estimates and forecastsAnalyst Forecast According to 10 analysts, the average rating for BMEA stock is "Strong Buy." The 12-month stock price forecast is $47.7, which is an increase of 185.97% from the latest price.